Definition

Seroquel XR Formulary Tool

Seroquel XR (quetiapine fumarate) is covered for 88% of patients nationwide with no prior authorization.1*†

  1. * Individual plan coverage may vary.
  2. † "Patients" means all covered lives (commercial, Medicare, and Medicaid) at Tiers 1-7 in the US, calculated by Fingertip Formulary® as of June 2009, that do not require additional information to the health plan in order for Seroquel XR to be covered. Data include covered lives whose prescriptions may be subject to step therapy requirements.

The Seroquel XR Formulary Database is a simple-to-use tool that allows you to determine Seroquel XR coverage for health plans specific to your area. To start, select your state and up to 6 health plans. Your results will show available coverage and any restrictions that may apply.

STEP 1

Select Your State

After selecting a state, a list of health plans in your area will appear.

STEP 2

Select Your Health Plan

Select your plan type

Once you choose a plan type, you may select up to 6 health plans and compare SEROQUEL XR coverage in your area.

Choose health plan(s)

STEP 3

Results

Print your results or change your selections.

Data updated as of November 2009. This information is provided for general purposes only and is not an endorsement of any particular health plan. Individual plans may vary and all information is subject to change. For the most current formulary information, contact your patient's drug benefit provider.
 
SEROQUEL XR

Seroquel XR (quetiapine fumarate) is covered for 88% of patients nationwide with no prior authorization.1*†

  1. * Individual plan coverage may vary.
  2. † "Patients" means all covered lives (commercial, Medicare, and Medicaid) at Tiers 1-7 in the US, calculated by Fingertip Formulary® as of June 2009, that do not require additional information to the health plan in order for Seroquel XR to be covered. Data include covered lives whose prescriptions may be subject to step therapy requirements.

The Seroquel XR Formulary Database is a simple-to-use tool that allows you to determine Seroquel XR coverage for health plans specific to your area. To start, select your state and up to six health plans. Your results will show available coverage and any restrictions that may apply.

Results
 
 
 
N/A
Not applicable.

Not Covered
Drugs that are not covered by the plan.

Patient pays the difference
Patient pays the difference means that the plan requires that the patient pay the difference in cost between the brand product and the generic product.

Tier 1
This drug is available at the lowest co-pay. Most commonly, these are generic drugs.

Tier 2
This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.

Tier 3
This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" (off formulary) brand drugs.

   Tier 4
This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" (off formulary) brand drugs or specialty prescription products.

Tier 5
This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" (off formulary) brand drugs or specialty prescription products.

Tier 6
This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" (off formulary) brand drugs or specialty prescription products.

Tier 7
This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" (off formulary) brand drugs or specialty prescription products.
OR (Other Restrictions)
Drugs with additional restrictions. An example is limitations that apply to certain strengths.

PA (Prior Authorization)
Drugs that require prior authorization. Typically, your doctor must provide additional information to your health plan in order for these drugs to be covered.

QL (Quantity Limits)
Drugs that have quantity limits with each prescription.

   ST (Step Therapy)
Drugs that include step therapy. Typically, your doctor must provide additional information to your health plan in order for these drugs to be covered.
 

Indications

Seroquel XR is indicated for the treatment of acute depressive episodes associated with bipolar disorder; acute manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or divalproex; maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex, and acute and maintenance treatment of schizophrenia. Seroquel is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment and the appropriate dose.

Important Safety Information for Seroquel XR and Seroquel® (quetiapine fumarate) tablets

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). Seroquel XR and Seroquel are not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Seroquel XR and Seroquel are not approved for use in patients under the age of 18 years. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose ≥126 mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients receiving placebo (mean exposure 152 days).

Clinically significant increases in cholesterol (7%-16% for quetiapine vs 3%-9% for placebo) and triglycerides (8%-23% for quetiapine vs 5%-16% for placebo) have been observed in clinical trials.

The proportion of patients in clinical trials meeting a weight gain criterion of ≥7% of body weight was 5%-23% for quetiapine vs 0%-7% for placebo.

A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs.

Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including quetiapine. Patients with a pre-existing low white blood cell (WBC) count or a history of drug induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, Seroquel XR and Seroquel should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and Seroquel XR and Seroquel should be discontinued in any patient if the absolute neutrophil count is <1000/mm3.

Tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs administered to the patient increase. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. Quetiapine should be prescribed in a manner that is most likely to minimize the occurrence of TD.

Warnings and Precautions also include the risk of orthostatic hypotension, cataracts, seizures, hyperprolactinemia, and dysphagia. Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment or shortly thereafter, and at 6-month intervals during chronic treatment. The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder, and close supervision of high risk patients should accompany drug therapy.

The most commonly reported adverse reactions associated with the use of Seroquel XR vs placebo in clinical trials for schizophrenia and bipolar disorder were somnolence (25%-52% vs 10%-13%), dry mouth (12%-37% vs 1%-7%), constipation (6%-10% vs 3%-6%), dyspepsia (5%-7% vs 1%-4%), dizziness (10%-13% vs 4%-11%), orthostatic hypotension (7% vs 5%), weight gain (7% vs 1%), increased appetite (12% vs 6%), fatigue (6%-7% vs 2%-4%), dysarthria (5% vs 0%), and nasal congestion (5% vs 1%). The most commonly reported adverse reactions associated with the use of Seroquel vs placebo in clinical trials for schizophrenia and bipolar disorder were somnolence (18%-57% vs 8%-15%), dry mouth (9%-44% vs 3%-13%), dizziness (9%-18% vs 5%-7%), constipation (8%-10% vs 3%-5%), asthenia (5%-10% vs 3%-4%), abdominal pain (4%-7% vs 1%-3%), postural hypotension (4%-7% vs 1%-2%), pharyngitis (4%-6% vs 3%), weight gain (5%-6% vs 1%-3%), lethargy (5% vs 2%), nasal congestion (5% vs 3%), SGPT increased (5% vs 1%), and dyspepsia (5%-7% vs 1%-4%).

Please see Prescribing Information for Seroquel XR, including Boxed Warnings.

Please see Prescribing Information for Seroquel, including Boxed Warnings.

References:

  1. Fingertip Formulary, June 26, 2009.

Your opinion matters to us

In an effort to improve SeroquelXR.com and make sure it continues to meet your needs, we would like to invite you to take a short survey that should take you only a few minutes to complete. Learning more from the health care professionals who use the site can help us continually improve it. Please be assured that your responses to the survey will not be linked to any personal information you may have provided elsewhere while visiting this site. You will not be asked to provide your name or contact information in order to complete the survey. All survey results will remain confidential, and will be used solely for the purpose of improving the content of this website for future visitors.

Close